Apolipoprotein mimetic peptides: A new approach for the treatment of asthma

Frontiers in Pharmacology

Volumn 3 MAR, Issue , 2012, Pages

  Yao, Xianglan ^a   Vitek, Michael P ^b   Remaley, Alan T ^a   Levine, Stewart J ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b Optimal Screening Vehicles Division   (United States)

Author keywords

Apolipoprotein A I; Apolipoprotein ai mimetic peptide; Apolipoprotein E; Apolipoprotein E mimetic peptide; Asthma

Indexed keywords

5A APOLIPOPROTEIN A1 MIMETIC PEPTIDE; ABC TRANSPORTER A1; ANTIASTHMATIC AGENT; APOLIPOPROTEIN A1; APOLIPOPROTEIN A1 MIMETIC PEPTIDE; APOLIPOPROTEIN E; APOLIPOPROTEIN E MIMETIC PEPTIDE; APOLIPOPROTEIN E3; APOLIPOPROTEIN E4; ARGINASE 1; ASPARTYLTRYPTOPHYLLEUCYLLYSYLALANYLPHENYLALANYLTYROSYLASPARTYLYSYLVALYLALANYLGLUTAMYLLYSYLLEUCYLLYSYLGLUTAMYLALANYLPHENYLALANINE; ASPARTYLTRYPTOPHYLLEUCYLLYSYLALANYLPHENYLALANYLTYROSYLASPARTYLYSYLVALYLALANYLGLUTAMYLLYSYLLEUCYLLYSYLGLUTAMYLALANYLPHENYLALANYLPROPYLASPARTYLTRYPTOPHYLALANYLLYSYLALANYLALANYLTYROSYLASPARTYLLYSYLALANYLALANYLGLUTAMYLLYSLALANYLLYSYLGLUTAMYLALANYLALANYL; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CHITINASE; CORTICOSTEROID; EOTAXIN; IMMUNOGLOBULIN E; INTERLEUKIN 17; INTERLEUKIN 3; INTERLEUKIN 4; LOW DENSITY LIPOPROTEIN RECEPTOR; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 3; OMALIZUMAB; OVALBUMIN; PEPTIDOMIMETIC AGENT; STEROID; THYMUS AND ACTIVATION REGULATED CHEMOKINE; TRANSCRIPTOME; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACUTE CORONARY SYNDROME; AIRWAY OBSTRUCTION; AIRWAY REMODELING; ALLELE; ALLERGIC AIRWAY INFLAMMATION; ANAPHYLAXIS; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASEPTIC NECROSIS; ASTHMA; BRONCHUS HYPERREACTIVITY; CELL HYPERPLASIA; CHRONIC DRUG ADMINISTRATION; DERMATOPHAGOIDES; DIABETES MELLITUS; DISEASE CONTROL; DISEASE MODEL; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG RESEARCH; DRUG RESISTANCE; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG WITHDRAWAL; EOSINOPHILIA; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GOBLET CELL; GOBLET CELL HYPERPLASIA; HUMAN; HYPERTENSION; IMMUNE DEFICIENCY; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOMODULATION; LIPID TRANSPORT; LUNG ALVEOLUS EPITHELIUM; LUNG ALVEOLUS MACROPHAGE; LUNG LAVAGE; MOLECULARLY TARGETED THERAPY; NONHUMAN; PATHOGENESIS; PHENOTYPE; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIDE EFFECT; TH17 CELL; TH2 CELL; TREATMENT RESPONSE; WEIGHT GAIN;

EID: 84864311113     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2012.00037     Document Type: Article

References (66)

1. Allan, L. L., Hoefl, K., Zheng, D. J., Chung, B. K., Kozak, F. K., Tan, R., and van den Elzen, P. (2009). Apolipoproteinmediated lipid antigen presentation in B cells provides a pathway for innate help by NKT cells. Blood 114, 2411-2416.
2. Amar, M. J., D'Souza, W., Turner, S., Demosky, S., Sviridov, D., Stonik, J., Luchoomun, J., Voogt, J., Hellerstein, M., and Remaley, A. T. (2010). 5A apolipoprotein mimetic peptide promotes cholesterol efflux and reduces atherosclerosis in mice. J. Pharmacol. Exp. Ther. 334, 634-641.
3. American Thoracic Society. (2000). Proceedings of the ATS workshop on refractory asthma: current understanding, recommendations, and unanswered questions. Am. J. Respir. Crit. Care Med. 162, 2341-2351.
4. Anantharamaiah, G. M., Jones, J. L., Brouillette, C. G., Schmidt, C. F., Chung, B. H., Hughes, T. A., Bhown, A. S., and Segrest, J. P. (1985). Studies of synthetic peptide analogs of the amphipathic helix. Structure of complexes with dimyristoyl phosphatidylcholine. J. Biol. Chem. 260, 10248-10255.
5. Anantharamaiah, G. M., Mishra, V. K., Garber, D. W., Datta, G., Handattu, S. P., Palgunachari, M. N., Chaddha, M., Navab, M., Reddy, S. T., Segrest, J. P., and Fogelman, A. M. (2007). Structural requirements for antioxidative and anti-inflammatory properties of apolipoprotein A-I mimetic peptides. J. Lipid Res. 48, 1915-1923.
6. Barnes, P. J. (2011). Biochemical basis of asthma therapy. J. Biol. Chem. 286, 32899-32905.
7. Bloedon, L. T., Dunbar, R., Duffy, D., Pinell-Salles, P., Norris, R., DeG-root, B. J., Movva, R., Navab, M., Fogelman, A. M., and Rader, D. J. (2008). Safety, pharmacokinetics, and pharmacodynamics of oral apoA-I mimetic peptide D-4F in highrisk cardiovascular patients. J. Lipid Res. 49, 1344-1352.
8. Braman, S. S. (2006). The global burden of asthma. Chest 130(1 Suppl.), 4S-12S.
9. Bu, G. (2009). Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy. Nat. Rev. Neurosci. 10, 333-344.
10. Burt, T. D., Agan, B. K., Marconi, V. C., He, W., Kulkarni, H., Mold, J. E., Cavrois, M., Huang, Y., Mahley, R. W., Dolan, M. J., J. M. McCune, and Ahuja, S. K. (2008). Apolipoprotein (apo) E4 enhances HIV-1 cell entry in vitro, and the APOE epsilon4/epsilon4 genotype accelerates HIV disease progression. Proc. Natl. Acad. Sci. U.S.A. 105, 8718-8723.
11. Castro, M., Rubin, A. S., Laviolette, M., Fiterman, J., De Andrade Lima, M., Shah, P. L., Fiss, E., Olivenstein, R., Thomson, N. C., Niven, R. M., Pavord, I. D., Simoff, M., Duhamel, D. R., McEvoy, C., Barbers, R., Ten Hacken, N. H., Wechsler, M. E., Holmes, M., Phillips, M. J., Erzurum, S., Lunn, W., Israel, E., Jarjour, N., Kraft, M., Shargill, N. S., Quiring, J., Berry, S. M., and Cox, G. (2010). Effectiveness and safety of bronchial thermoplasty in the treatment of severe asthma: a multicenter, randomized, doubleblind, shamcontrolled clinical trial. Am. J. Respir. Crit. Care Med. 181, 116-124.
12. Chang, K. S., Jiang, J., Cai, Z., and Luo, G. (2007). Human apolipoprotein e is required for infectivity and production of hepatitis C virus in cell culture. J. Virol. 81, 13783-13793.
13. Chen, J., Chen, Z., Chintagari, N. R., Bhaskaran, M., Jin, N., Narasaraju, T., and Liu, L. (2006). Alveolar type I cells protect rat lung epithelium from oxidative injury. J. Physiol. (Lond.) 572(Pt 3), 625-638.
14. Christensen, D. J., Ohkubo, N., Oddo, J., Van Kanegan, M. J., Neil, J., Li, F., Colton, C. A., and Vitek, M. P. (2011). Apolipoprotein E and peptide mimetics modulate inflammation by binding the SET protein and activating protein phosphatase 2A. J. Immunol. 186, 2535-2542.
15. Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., and Pericak-Vance, M. A. (1993). Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261, 921-923.
16. Crimi, E., Spanevello, A., Neri, M., Ind, P. W., Rossi, G. A., and Brusasco, V. (1998). Dissociation between airway inflammation and airway hyperresponsiveness in allergic asthma. Am. J. Respir. Crit. Care Med. 157, 4-9.
17. Cun, W., Jiang, J., and Luo, G. (2010). The C-terminal alphahelix domain of apolipoprotein E is required for interaction with nonstructural protein 5A and assembly of hepatitis C virus. J. Virol. 84, 11532-11541.
18. De Alba, J., Raemdonck, K., Dekkak, A., Collins, M., Wong, S., Nials, A. T., Knowles, R. G., Belvisi, M. G., and Birrell, M. A. (2009). HDM induces direct airway inflammation in vivo: implications for future disease therapy? Eur. Respir. J. 35, 1377-1387.
19. D'Souza, W., Stonik, J. A., Murphy, A., Demosky, S. J., Sethi, A. A., Moore, X. L., Chin-Dusting, J., Remaley, A. T., and Sviridov, D. (2010). Structure/function relationships of apolipoprotein a-I mimetic peptides: implications for antiatherogenic activities of highdensity lipoprotein. Circ. Res. 107, 217-227.
20. Fanta, C. H. (2009). Asthma. N. Engl. J. Med. 360, 1002-1014.
21. Finkelman, F. D., Hogan, S. P., Hershey, G. K., Rothenberg, M. E., and Wills-Karp, M. (2010). Importance of cytokines in murine allergic airway disease and human asthma. J. Immunol. 184, 1663-1674.
22. Goldstein, J. L., and Brown, M. S. (2009). The LDL receptor. Arterioscler. Thromb. Vasc. Biol. 29, 431-438.
23. Hill, J. M., Bhattacharjee, P. S., and Neumann, D. M. (2007). Apolipoprotein E alleles can contribute to the pathogenesis of numerous clinical conditions including HSV-1 corneal disease. Exp. Eye Res. 84, 801-811.
24. Johnson, J. R., Wiley, R. E., Fattouh, R., Swirski, F. K., Gajewska, B. U., Coyle, A. J., Gutierrez-Ramos, J. C., Ellis, R., Inman, M. D., and Jordana, M. (2004). Continuous exposure to house dust mite elicits chronic airway inflammation and structural remodeling. Am. J. Respir. Crit. Care Med. 169, 378-385.
25. Kellner-Weibel, G., and de la Llera-Moya, M. (2011). Update on HDL receptors and cellular cholesterol transport. Curr. Atheroscler. Rep. 13, 233-241.
26. Lalazar, A., Weisgraber, K. H., Rall, S. C. Jr., Giladi, H., Innerarity, T. L., Levanon, A. Z., Boyles, J. K., Amit, B., Gorecki, M., Mahley, R. W., and Vogel, T. (1988). Sitespecific mutagenesis of human apolipoprotein E. Receptor binding activity of variants with single amino acid substitutions. J .Biol. Chem. 263, 3542-3545.
27. Lambrecht, B. N., and Hammad, H. (2009). Biology of lung dendritic cells at the origin of asthma. Immunity 31, 412-424.
28. Laskowitz, D. T., Thekdi, A. D., Thekdi, S. D., Han, S. K., Myers, J. K., Pizzo, S. V., and Bennett, E. R. (2001). Downregulation of microglial activation by apolipoprotein E and apoE-mimetic peptides. Exp. Neurol. 167, 74-85.
29. Levitt, R. C., and Mitzner, W. (1988). Expression of airway hyperreactivity to acetylcholine as a simple autosomal recessive trait in mice. FASEB J. 2, 2605-2608.
30. Long, A. J., Sypek, J. P., Askew, R., Fish, S. C., Mason, L. E., Williams, C. M., and Goldman, S. J. (2006). Gob-5 contributes to goblet cell hyperplasia and modulates pulmonary tissue inflammation. Am. J. Respir. Cell Mol. Biol. 35, 357-365.
31. Lynch, J. R., Tang, W., Wang, H., Vitek, M. P., Bennett, E. R., Sullivan, P. M., Warner, D. S., and Laskowitz, D. T. (2003). APOE genotype and an ApoE-mimetic peptide modify the systemic and central nervous system inflammatory response. J. Biol. Chem. 278, 48529-48533.
32. Mahley, R. W. (1988). Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science 240, 622-630.
33. Mahley, R. W., Weisgraber, K. H., and Huang, Y. (2009). Apolipoprotein E: structure determines function, from atherosclerosis to Alzheimer's disease to AIDS. J. Lipid Res. 50(Suppl.), S183-S188.
34. Massaro, D., and Massaro, G. D. (2008). Apoetm1Unc mice have impaired alveologenesis, low lung function, and rapid loss of lung function. Am. J. Physiol. Lung Cell. Mol. Physiol. 294, L991-L997.
35. Moore, W. C., Bleecker, E. R., Curran-Everett, D., Erzurum, S. C., Ameredes, B. T., Bacharier, L., Calhoun, W. J., Castro, M., Chung, K. F., Clark, M. P., Dweik, R. A., Fitzpatrick, A. M., Gaston, B., Hew, M., Hussain, I., Jarjour, N. N., Israel, E., Levy, B. D., Murphy, J. R., Peters, S. P., Teague, W. G., Meyers, D. A., Busse, W. W., and Wenzel, S. E. (2007). Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's Severe Asthma Research Program. J. Allergy Clin. Immunol. 119, 405-413.
36. Murphy, A. J., Woollard, K. J., Hoang, A., Mukhamedova, N., Stirzaker, R. A., McCormick, S. P., Remaley, A. T., Sviridov, D., and Chin-Dusting, J. (2008). Highdensity lipoprotein reduces the human monocyte inflammatory response. Arterioscler. Thromb. Vasc. Biol. 28, 2071-2077.
37. Nandedkar, S. D., Weihrauch, D., Xu, H., Shi, Y., Feroah, T., Hutchins, W., Rickaby, D. A., Duzgunes, N., Hillery, C. A., Konduri, K. S., and Pritchard, K. A. Jr. (2011). D-4F, an ApoA-1 mimetic, decreases airway hyperresponsiveness, inflammation and oxidative stress in a murine model of asthma. J. Lipid Res. 52, 499-508.
38. Navab, M., Anantharamaiah, G. M., Hama, S., Garber, D. W., Chaddha, M., Hough, G., Lallone, R., and Fogelman, A. M. (2002). Oral administration of an Apo A-I mimetic peptide synthesized from D-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol. Circulation 105, 290-292.
39. Navab, M., Reddy, S. T., Van Lenten, B. J., and Fogelman, A. M. (2011). HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms. Nat. Rev. Cardiol. 8, 222-232
40. Nissen, S. E., Tsunoda, T., Tuzcu, E. M., Schoenhagen, P., Cooper, C. J., Yasin, M., Eaton, G. M., Lauer, M. A., Sheldon, W. S., Grines, C. L., Halpern, S., Crowe, T., Blankenship, J. C., and Kerensky, R. (2003). Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 290, 2292-2300.
41. Nofer, J. R., and Remaley, A. T. (2005). Tangier disease: still more questions than answers. Cell.Mol.LifeSci.62, 2150-2160.
42. Osei-Hwedieh, D. O., Amar, M., Sviridov, D., and Remaley, A. T. (2011). Apolipoprotein mimetic peptides: Mechanisms of action as antiatherogenic agents. Pharmacol. Ther. 130, 83-91.
43. Pendse, A. A., Arbones-Mainar, J. M., Johnson, L. A.,Altenburg, M. K., and Maeda, N. (2009). Apolipoprotein E knockout and knockin mice: atherosclerosis, metabolic syndrome, and beyond. J. Lipid Res. 50(Suppl.), S178-S182.
44. Remaley, A. T., Amar, M., and Sviridov, D. (2008). HDL-replacement therapy: mechanism of action, types of agents and potential clinical indications. Expert Rev. Cardiovasc. Ther. 6, 1203-1215.
45. Remaley, A. T., Thomas, F., Stonik, J. A., Demosky, S. J., Bark, S. E., Neufeld, E. B., Bocharov, A. V., Vishnyakova, T. G., Patterson, A. P., Eggerman, T. L.,Santamarina-Fojo, S., and Brewer, H. B. (2003). Synthetic amphipathic helical peptides promote lipid efflux from cells by an ABCA1-dependent and an ABCA1-independent pathway. J. Lipid Res. 44, 828-836.
46. Schaefer, E. J., Gregg, R. E., Ghiselli, G., Forte, T. M., Ordovas, J. M., Zech, L. A., and Brewer, H. B. Jr. (1986). Familial apolipoprotein E deficiency. J. Clin. Invest. 78, 1206-1219.
47. Sears, M. R., Greene, J. M., Willan, A. R., Wiecek, E. M., Taylor, D. R., Flannery, E. M., Cowan, J. O., Herbison, G. P., Silva, P. A., and Poulton, R. (2003). A longitudinal, populationbased, cohort study of childhood asthma followed to adulthood. N. Engl.J.Med.349, 1414-1422.
48. Segrest, J. P., Garber, D. W., Brouillette, C. G., Harvey, S. C., and Anantharamaiah, G. M. (1994). The amphipathic alpha helix: a multifunctional structural motif in plasma apolipoproteins. Adv. Protein Chem. 45, 303-369.
49. Sethi, A. A., Amar, M., Shamburek, R. D., and Remaley, A. T. (2007). Apolipoprotein AI mimetic peptides: possible new agents for the treatment of atherosclerosis. Curr. Opin. Investig. Drugs 8, 201-212.
50. Sethi, A. A., Stonik, J. A., Thomas, F., Demosky, S. J., Amar, M., Neufeld, E., Brewer, H. B., Davidson, W. S., D'Souza, W., Sviridov, D., and Remaley, A. T. (2008). Asymmetry in the lipid affinity of bihelical amphipathic peptides. A structural determinant for the specificity of ABCA1-dependent cholesterol efflux by peptides. J. Biol. Chem. 283, 32273-32282.
51. Simpson, J. L., Powell, H., Boyle, M. J., Scott, R. J., and Gibson, P. G. (2008). Clarithromycin targets neutrophilic airway inflammation in refractory asthma.Am. J. Respir. Crit. Care Med. 177, 148-155.
52. Sorkness, R. L., Bleecker, E. R., Busse, W. W., Calhoun, W. J., Castro, M., Chung, K. F., Curran-Everett, D., Erzurum, S. C., Gaston, B. M., Israel, E., Jarjour, N. N., Moore, W. C., Peters, S. P., Teague, W. G., and Wenzel, S. E. (2008). Lung function in adults with stable but severe asthma: air trapping and incomplete reversal of obstruction with bronchodilation. J. Appl. Physiol. 104, 394-403.
53. Strunk, R. C., and Bloomberg, G. R. (2006). Omalizumab for asthma. N. Engl.J.Med.354, 2689-2695.
54. Suzuki, T., Yamaya, M., Kamanaka, M., Jia, Y. X., Nakayama, K., Hosoda, M., Yamada, N., Nishimura, H., Sekizawa,K.,and Sasaki,H. (2001). Type 2 rhinovirus infection of cultured human tracheal epithelial cells: role of LDL receptor. Am. J. Physiol. Lung Cell. Mol. Physiol. 280, L409-L420.
55. Swedin, L., Neimert-Andersson, T., Hjoberg, J., Jonasson, S., van Hage, M., Adner, M., Ryrfeldt, A., and Dahlen, S. E. (2009). Dissociation of airway inflammation and hyperresponsiveness by cyclooxygenase inhibition in allergen challenged mice. Eur. Respir. J. 34, 200-208.
56. Tabet, F., Remaley, A. T., Segaliny, A. I., Millet, J., Yan, L., Nakhla, S., Barter, P. J., Rye, K. A., and Lambert, G. (2010). The 5A apolipoprotein A-I mimetic peptide displays antiinflammatory and antioxidant properties in vivo and in vitro. Arterioscler. Thromb. Vasc. Biol. 30, 246-252.
57. Tardif, J. C., Gregoire, J., L'Allier, P. L., Ibrahim, R., Lesperance, J., Heinonen, T. M., Kouz, S., Berry, C., Basser, R., Lavoie, M. A., Guertin, M. C., and Rodes-Cabau, J. (2007). Effects of reconstituted highdensity lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. JAMA 297, 1675-1682.
58. Thomas, W. R., Smith, W. A., Hales, B. J., Mills, K. L., and O'Brien, R. M. (2002). Characterization and immunobiology of house dust mite allergens. Int. Arch. Allergy Immunol. 129, 1-18.
59. van den Elzen, P., Garg, S., Leon, L., Brigl, M., Leadbetter, E. A., Gumperz, J. E., Dascher, C. C., Cheng, T. Y., Sacks, F. M., Illarionov, P. A., Besra, G. S., Kent, S. C., Moody, D. B., and Brenner, M. B. (2005). Apolipoproteinmediated pathways of lipid antigen presentation. Nature 437, 906-910.
60. Wang, W., Xu, H., Shi, Y., Nandedkar, S., Zhang, H., Gao, H., Feroah, T., Weihrauch, D., Schulte, M. L., Jones, D. W., Jarzembowski, J., Sorci-Thomas, M., and Pritchard, K. A. Jr. (2010). Genetic deletion of apolipoprotein A-I increases airway hyperresponsiveness, inflammation, and collagen deposition in the lung. J. Lipid Res. 51, 2560-2570.
61. Wark, P. A., and Gibson, P. G. (2006). Asthma exacerbations. 3: Pathogenesis. Thorax 61, 909-915.
62. Watson, C. E., Weissbach, N., Kjems, L., Ayalasomayajula, S., Zhang, Y., Chang, I., Navab, M., Hama, S., Hough, G., Reddy, S. T., Soffer, D., Rader, D. J., Fogelman, A. M., and Schecter, A. (2011). Treatment of patients with cardiovascular disease with L-4F, an Apo-A1 mimetic, did not improve select biomarkers of HDL function. J. Lipid Res. 52, 361-373.
63. Wills-Karp, M., and Ewart, S. L. (1997). The genetics of allergeninduced airway hyperresponsiveness in mice. Am. J. Respir. Crit. Care Med. 156(4 Pt 2), S89-S96.
64. Yao, X., Dai, C., Fredriksson, K., Dagur, P. K., Mccoy, J. P., Qu, X., Yu, Z. X., Keeran, K. J., Zywicke, G. J., M.Amar, J. A., Remaley, A. T., and Levine, S. J. (2011). 5A, an apolipoprotein A-I mimetic peptide, attenuates the induction of house dust miteinduced asthma. J. Immunol. 186, 576-583.
65. Yao, X., Remaley, A. T., and Levine, S. J. (2011). New kids on the block: the emerging role of apolipoproteins in the pathogenesis and treatment of asthma. Chest 140, 1048-1054.
66. Yao, X., Fredriksson, K., Yu, Z. X., Xu, X., Raghavachari, N., Keeran, K. J., Zywicke, G. J., Kwak, M., Amar, M. J., Remaley, A. T., and Levine, S. J. (2010). Apolipoprotein E negatively regulates house dust miteinduced asthma via a LDL receptormediated Pathway. Am. J. Respir. Crit. Care Med. 182, 1228-1238.